Form 4: Liquidia CEO Roger Jeffs Sells Shares via 10b5-1 Plan

Liquidia Corporation CEO Roger Jeffs sold 18,839 shares of common stock at an average price of $40.60 per share.

Summary

• CEO Roger Jeffs executed a sale of 18,839 shares of Liquidia Corp common stock on April 17, 2026.
• The shares were sold at a volume-weighted average price of $40.6049, with individual transaction prices ranging from $40.00 to $41.85.
• The transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on November 5, 2025.
• Following the sale, the reporting person maintains beneficial ownership of 1,137,599 shares directly and 1,469,690 shares indirectly through a trust and an LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-planned 10b5-1 arrangement and represents a small fraction of the CEO's total holdings.

Positives

• The sale was executed via a pre-planned Rule 10b5-1 program, which is a standard mechanism for executives to sell shares without triggering concerns regarding insider trading based on non-public information.

Negatives

• The transaction represents a divestment of equity by the company's Chief Executive Officer.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity may signal ongoing executive divestment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are common in the biotechnology sector, often used for personal financial planning rather than reflecting a change in sentiment regarding the company's clinical or commercial prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage equity holdings while maintaining compliance with SEC regulations.
• The scale of the sale relative to the CEO's total holdings (approximately 0.7% of total beneficial ownership) is considered minor and typical for executive compensation liquidity events.

Related Party Transactions

• Securities held by Roger A. Jeffs Living Trust.
• Securities held by Serendipity BioPharma LLC, where the reporting person is a manager.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the CEO's total equity stake.

Next Steps

• Continued monitoring of future Form 4 filings for additional insider activity.

Key Dates

Keywords

Liquidia, LQDA, Insider Trading, Form 4, Roger Jeffs, Biopharma